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In Brief
The transcription factor Tcf1 is
downregulated during CD8 effector
differentiation. Danilo et al. show that
IL-12 suppresses Tcf1 in primed CD8
T cells. Tcf1 suppression requires cell
cycling, is transcriptional, and is
mediated in part by DNA methylation.
Inflammation-induced Tcf1
downregulation facilitates effector
differentiation by de-repressing IL-12Rb2
and BLIMP1.
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The formation of central CD8 T cell memory in
response to infection depends on the transcription
factor Tcf1 (Tcf7). Tcf1 is expressed at high levels
in naive CD8 T cells but downregulated in most
CD8 T cells during effector differentiation. The rele-
vance of Tcf1 downregulation for effector differenti-
ation and the signals controlling Tcf1 expression
have not been elucidated. Here, we show that sys-
temic inflammatory signals downregulated Tcf1 in
CD8 T cells during dendritic cell vaccination and
bacterial infections. The suppressive effect was
mediated by the inflammatory cytokine interleukin
12 (IL-12), which acted via STAT4 in CD8 T cells.
IL-12-induced Tcf1 downregulation required cell
cycling, occurred at the transcriptional level, and
was prevented in part by inhibiting DNA methyl-
transferases. Absence of Tcf1 during T cell priming
circumvented the need of systemic inflammation for
effector differentiation. We conclude that silencing
of Tcf1 by systemic inflammation facilitates effector
CD8 T cell differentiation.
INTRODUCTION
Pathogen recognition usually generates a large number of spe-
cific CD8 T cells that have acquired effector functions and are
needed to control intracellular pathogens (Kaech and Cui,
2012). These CD8 T cells are heterogeneous and have distinct
fates, which can be followed using cell-surface markers, at least
in response to certain infections. CD127 (IL7Ra) KLRG1+ CD8
T cells express high levels of cytotoxic effector molecules
(including granzymeB), butmost of these cells die once the path-
ogen is cleared (termed short-lived effector T cells [SLECs]). On
theother hand,CD127+KLRG1CD8Tcells (referred to asmem-
ory precursor effector T cells [MPECs]) can produce interleukin 2
(IL-2), are more likely to survive, and give rise to long-lived mem-
ory cells. Memory cells, which provide long-term protection from
infection (Kaech and Cui, 2012), are also heterogeneous. Among
recirculating memory cells, central memory cells (TCM: CD62L
+
CD127+) are generally better mediators of host protection than
effector memory cells (TEM: CD62L
 CD127+), as the formerCell Rep
This is an open access article under the CC BY-Ndisplay enhancedproliferative capacity in response to antigen re-
challenge (Sallusto et al., 1999).
Effector and memory CD8 T cell differentiation is directed by
multiple cell-extrinsic cues, which include antigen recognition,
co-stimulation, and cytokines (Chang et al., 2014; Kaech and
Cui, 2012). While antigen recognition and co-stimulation impact
CD8 T cell expansion and persistence, inflammatory cytokines,
such as IL-12 and type I interferon (IFN), or high levels of IL-2 pro-
mote effector differentiation (Kim and Harty, 2014). IL-12 chiefly
activates STAT4,which inducesT-bet (Tbx21) expression inListe-
ria monocytogenes infection (Joshi et al., 2007; Xiao et al., 2009).
IL-12 also inducesBlimp1 (Prdm1) in aSTAT4-dependentmanner
in Th1 cells (Neumann et al., 2014). T-bet (Tbx21) and Blimp1
(Prdm1), as well as Id2 and Zeb2, represent key transcription
factorsmediating terminalCD8effectorTcell differentiation (Dom-
inguez et al., 2015; Intlekofer et al., 2007; Joshi et al., 2007;Rutish-
auser et al., 2009; Takemoto et al., 2006; Yang et al., 2011).
Conversely, memory T cell formation is promoted by a distinct
set of transcription factors, including Eomes, Id3, Bcl6, and Tcf1
(encoded by the Tcf7 gene) (Chang et al., 2014; Ichii et al., 2004;
Jeannet et al., 2010; Ji et al., 2011; Kaech and Cui, 2012; Masson
et al., 2013; Yang et al., 2011; Zhou et al., 2010). The expression of
Eomes and Bcl6 can be induced by IL-21 and IL-10 in a STAT3-
dependent fashion (Cuiet al., 2011). Thus, effector versusmemory
CD8 T cell differentiation is regulated by distinct cytokines and
signaling pathways, which induce the expression of specific tran-
scription factors that promote or enforce specific cell fates.
While transcription factors promotingmemory, such as Eomes
and Bcl6, are induced during T cell differentiation, Tcf1 is ex-
pressed at high levels in naive CD8 T cells and downregulated
in most, but not all, cells during the primary CD8 T cell response
to viral or bacterial infection (Boudousquie´ et al., 2014; Jeannet
et al., 2010; Lin et al., 2016; Zhou et al., 2010). Similarly, most
CD8 T cells in chronic viral infection have downregulated Tcf1
and display an effector gene expression program (Utzschneider
et al., 2016; Im et al., 2016). Downregulation of Tcf1, which has
been associated with asymmetric partitioning of Tcf1 in dividing
CD8 T cells (Lin et al., 2016), thus correlates with effector differ-
entiation. However, whether Tcf1 downregulation is cause for or
a consequence of effector differentiation, andwhich signals sup-
press Tcf1 in vivo, are not known.
Using dendritic cell vaccination, we showed that systemic in-
flammatory signals downregulated Tcf1 in primed CD8 T cells.
Tcf1 suppressionwas chieflymediated by inflammatory cytokine
IL-12, which acted via IL-12Rb2 and STAT4 expressed in CD8orts 22, 2107–2117, February 20, 2018 ª 2018 The Author(s). 2107
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Tcf1 Downregulation Is Mediated by Systemic Inflam-
mation
(A) Experimental approach. P14 chimeric mice (i.e., B6.CD45.1 mice adop-
tively transferred with 104 naive P14 cells [CD45.2+]) were vaccinated with
LPS-matured, LCMV gp33-41 (gp33) peptide-pulsed dendritic cells (DC33)
without or in combination with CpG (i.p.) (DC33/CpG).
(B) Abundance of P14 cells (CD45.2+) in the spleen 7 days post-vaccination of
P14 chimeric mice with DC33 or DC33/CpG.
(C) Histogram overlays show Tcf1 expression in P14 cells (black open) relative
to host CD8 T cells (gray open) and to no antibody control (gray fill). Numbers
and bar graph depict the fraction of Tcf1low P14 cells.
2108 Cell Reports 22, 2107–2117, February 20, 2018T cells. IL-12-mediated Tcf1 downregulation depended on cell
cycling and occurred at the transcriptional level. Finally, Tcf1
downregulation in CD8 T cells was found to facilitate effector
differentiation.
RESULTS
Systemic Inflammation Downregulates Tcf1 in Primed
CD8 T Cells
While virtually all naive CD8 T cells express Tcf1, most CD8
T cells downregulate Tcf1 during the primary immune response
to infection, and this coincides with effector differentiation (Bou-
dousquie´ et al., 2014; Jeannet et al., 2010; Lin et al., 2016; Zhou
et al., 2010). However, it is not known how Tcf1 expression is
controlled and whether downregulation is cause for, or a conse-
quence of, effector differentiation.
We first addressed whether Tcf1 downregulation depended
on the T cell receptor (TCR) signal strength. We followed OT-1
TCR transgenic CD8 T cells responding to L.monocytogenes ex-
pressing the high-affinity ligand SIINFEKL (N4) or the low-affinity
ligand SIITFEKL (T4) (Zehn et al., 2009). 7 days after
L. monocytogenes N4 infection, OT-1 cells had massively
expanded, while expansion in L. monocytogenes T4 infections
was 20-fold reduced. In contrast, effector differentiation was
not very different (Figures S1A–S1C), in agreement with pub-
lished data (Oberle et al., 2016; Zehn et al., 2009). Further,
compared to naive OT-1 cells (not shown) or host CD8 T cells,
Tcf1 downregulation in OT-1 cells following L. monocytogenes
N4 and L. monocytogenes T4 infection was not very different,
albeit it was more prominent with L. monocytogenes. T4 (Fig-
ure S1D). Corresponding results were obtained when analyzing
the expression of the Tcf1 targetAxin2 (Figure S1E). Thus, during
a CD8 T cell response to infection, Tcf1 downregulation is only
modestly impacted by the strength of the TCR-peptide MHC
interaction and does not correlate with the extent of T cell
expansion.
We next addressed whether Tcf1 expression was regulated by
inflammation. To this end, we adopted a vaccination protocol us-
ing dendritic cell (DC) immunization as schematically shown in
Figure 1A. We generated P14 chimeric mice; i.e., B6 (CD45.1+)(D) IL-2 and IFN-g production by P14 cells following in vitro restimulation with
gp33 peptide. The bar graphs depict the percentage of IL-2+ (left) and IFN-g+
(right) P14 cells.
(E) Histogram overlays show granzyme B (GzmB) expression in P14 cells
(black open) compared to isotype control (gray fill). Numbers indicate mean
fluorescence intensity (MFI) of staining. The bar graph depicts the MFI of
GzmB staining whereby the background was subtracted.
(F) CD127 versus KLRG1 expression among gated P14 cells. The bar graphs
indicate the percentage of CD127 KLRG1+ SLEC (left) and CD127+ KLRG1
MPEC P14 cells (right).
(G and H) Histogram overlays show Tcf1 expression (G) or GzmB expression
(H) in gated CD127+ KLRG1 (black open) and CD127 KLRG1+ P14 cells
(gray open) compared to no antibody control (gray fill) and host CD8 T cells
(dotted border, gray fill). Numbers depict the fraction of Tcf1low P14 cells (G) or
the MFI of GzmB staining (H).
All bar graphs show means (±SD, n = 5). Data are representative of 2 or more
independent experiments. Statistical significance was determined using un-
paired t tests (***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant [p > 0.05]).
See also Figure S1.
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Figure 2. IL-12 (p40) Blockade Prevents Inflammation-Induced Tcf1
Downregulation
P14 chimeric mice were vaccinated with DC33/CpG and treated with isotype
control antibody (Ab) or anti-IL-12 (p40) Ab.
(A) Tcf1 expression in P14 cells (black open) compared to host CD8 T cells
(gray open) and no antibody control (gray fill). Numbers and bar graph depict
the percentage of Tcf1low cells in P14 cells.
(B) The bar graph depicts the abundance of P14 cells in the spleen.
(C) Production of IL-2 and IFN-g following in vitro restimulation. The bar graphs
depict the percentage of IL-2+ (left) and IFN-g+ (right) P14 cells.
(D) GzmB expression in P14 cells (black open) compared to isotype control
(gray fill). The bar graph depicts the MFI of GzmB staining whereby back-
ground was subtracted.
(E) CD127 versus KLRG1 expression among gated P14 cells. The bar graphs
show the percentage of CD127 KLRG1+ SLECs (left) and CD127+ KLRG1
MPECs (right).
Bar graphs show means (±SD, n = 5). Data are representative of at least 2
independent experiments. Statistical significance was determined using un-
paired t tests (***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant [p > 0.05]).
See also Figure S2.mice that were adoptively transferred with a small dose (104) of
naive P14 T cells (CD45.2+). The P14 TCR recognizes the lym-
phocytic choriomeningitis virus (LCMV)-derived gp33-41
epitope. Chimeric mice were vaccinated using bone-marrow-
derived DCs that had been matured using the TLR4 ligand lipo-
polysaccharide (LPS) and pulsed with LCMV gp33-41 peptide
(termed DC33). To address the role of systemic inflammation,
DC vaccination was combined with systemic exposure to the
TLR9 ligand CpG-B (termed DC33/CpG) (Badovinac et al.,
2005; Cui et al., 2009).
P14 CD8 T cells were below detection in the absence of vacci-
nation (data not shown) but were comparably abundant at day 7
post-DC33 and DC33/CpG vaccination (Figures 1B and S1F), inagreement with a previous study (Cui et al., 2009). Similar to
naive P14 cells (data not shown) or host CD8 T cells, most P14
cells expressed high levels of Tcf1 following DC33 vaccination
(Figure 1C). In contrast, DC33/CpG vaccination significantly
reduced Tcf1 expression in P14 cells (Figure 1C). Tcf1 downre-
gulation did not occur when CpG was administered in the
absence of DC33 vaccination (data not shown). Thus, systemic
inflammation suppressed Tcf1 in primed T cells. Corresponding
results were obtained when analyzing the expression of the Tcf1
target Axin2 (Figure S1G).
DC33-primed P14 cells efficiently produced IL-2 upon pep-
tide restimulation in vitro, expressed low levels of granzyme
B (GzmB), and were mostly CD127+ KLRG1 MPECs (Figures
1D–1F). In contrast, P14 cells primed with DC33/CpG produced
little IL-2, expressed higher levels of GzmB, and had a pre-
dominant CD127 KLRG1+ SLEC phenotype (Figures 1D–1F).
Nevertheless, Tcf1 expression was maintained in a subset of
cells with an MPEC phenotype (Figure 1G), and these cells
were undifferentiated based on a lack of granzyme B expres-
sion (Figure 1H). Thus, systemic inflammation repressed Tcf1
in most primed CD8 T cells and this correlated with effector
differentiation.
Tcf1 Downregulation Is Mediated by IL-12 (p40)
The data so far showed that TLR9 signaling played a key role for
suppressing Tcf1 and promoting effector differentiation of
primed CD8 T cells. TLR9 expression by the immunizing DCs
or the responding CD8 T cells are reportedly not essential for
effector differentiation (Pham et al., 2009), indicating a role for
soluble factors produced by host cells expressing TLR9.
DC/CpG vaccination increases serum levels of multiple cyto-
kines (Cui et al., 2014; Pham et al., 2009), including IL-12 and
type I IFN, as well as IL-2, which promotes effector CD8 T cell dif-
ferentiation (Joshi et al., 2007; Kalia et al., 2010; Keppler et al.,
2012; Williams et al., 2006; Xiao et al., 2009). We thus tested
whether these cytokines downregulated Tcf1 in the context of
DC33/CpG vaccination. Indeed, blockade of IL-12 (p40) almost
completely prevented Tcf1 downregulation in CD8 T cells (Fig-
ure 2A). IL-12 (p40) blockade did not significantly impact P14
expansion (Figure 2B) but prevented effector differentiation as
judged by enhanced IL-2 production, reduced GzmB expres-
sion, and reduced SLEC differentiation (Figures 2C–2E). In
contrast, blockade of interferon-a/b receptor 1 (IFNAR1) or IL-2
had essentially no effect on Tcf1 expression or effector differen-
tiation (Figure S2). Thus, Tcf1 repression in primed CD8 T cells
chiefly depends on IL-12 (p40).
Tcf1 Downregulation Is Mediated by IL-12Rb2-STAT4
Signaling in CD8 T Cells
Since IL-12 (p40) is a subunit of IL-12 and IL-23, we next ad-
dressed whether both cytokines suppressed Tcf1 and whether
they acted directly on CD8 T cells. When CD8 T cells were acti-
vated with anti-CD3 plus anti-CD28 monoclonal antibody (mAb)
in vitro, Tcf1 expression remained comparable to nonactivated
cells but was reduced when IL-12 was added (Figure S3A). In
contrast, IL-23 had no effect (Figure S3B). Corresponding data
were obtained when P14 cells were stimulated with gp33 pep-
tide-pulsed splenocytes (Figure S3C). We tested additionalCell Reports 22, 2107–2117, February 20, 2018 2109
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Figure 4. IL-12 Represses Tcf7 Transcription
and Establishes Asymmetric Tcf1 Abundance
during Cell Division
(A–C) Carboxyfluorescein succinimidyl ester
(CFSE)-labeled P14 cells (CD45.2+) were acti-
vated in vitro with gp33 peptide-pulsed spleno-
cytes (CD45.1+ or CD45.1+/2+). Representative
flow cytometry plots show CFSE dilution versus
Tcf1 expression at the indicated time point post
stimulation in the absence of IL-12 (A), in the
presence of IL-12 (B), and upon addition of IL-12
and the cell-cycle inhibitor aphidicolin at 48 hr
post-stimulation (C). Numbers indicate the frac-
tion cells in the respective quadrants. Note that
CFSE was gated according to residual CFSE
expression observed at 48 hr post-stimulation.
The data shown are representative of 3 inde-
pendent experiments.
(D) P14 cells were activated as above for 72 hr, and
Tcf7mRNA levels were determined using qRT-PCR
analysis. Data shown represent quadruplicate determinations and are representative of 2 independent experiments.
(E) P14 cells were activated as above, and the DNA methyltransferase inhibitor decitabine (black border, gray fill) or vehicle (DMSO) (gray border, open) was
added at 48 hr post stimulation. Tcf1 expression was measured at 72 hr post-stimulation. The bar graph depicts the mean MFI (±SD) of Tcf1 expression
normalized to P14 cells activated with gp33 + IL-12 (100%) from n = 4 (vehicle) or n = 8 (decitabine) independent determinations.
Statistical significance was determined using an unpaired t test (***p < 0.001; *p < 0.05; ns, not significant [p > 0.05]). See also Figure S3.inflammatory cytokines and found that IFN-b also suppressed
Tcf1, albeit weakly as compared to IL-12 (Figure S3C).
We next used IL12Rb2/ CD8 T cells to address whether
IL-12 acted directly on CD8 T cells during DC vaccination. Since
IL-12Rb2 chiefly signals via STAT4 (Jacobson et al., 1995;
Nguyen et al., 2002), we further tested whether STAT4 played
a role. Following DC33/CpG vaccination, Tcf1 downregulation
was significantly less efficient when P14 cells lacked IL12Rb2
or STAT4 (Figure 3A). This was associated with increased IL-2
production and reduced SLEC differentiation (Figures 3B and
3D), in agreement with Keppler et al. (2009). Thus, IL-12Rb2-
STAT4 signaling in CD8 T cells downregulates Tcf1 and induces
effector differentiation. However, the effect of IL-12Rb2-STAT4
deficiency was reduced compared to IL-12 (p40) blockade, indi-
cating that IL-12 acts in part indirectly. The reduced effect of
IL12Rb2 or STAT4-deficiency likely explains why there was no
significant change in GzmB expression (Figure 3C). Irrespec-
tively, IL-12Rb2-STAT4 signaling in CD8 T cells contributes to
DC33/CpG-vaccine-induced Tcf1 downregulation.
We further determined the importance of the IL-12Rb2-STAT4
axis for Tcf1 expression in CD8 T cells responding to an acute
infection. Infection with L. monocytogenes expressing gp33
(L.m.-gp33) resulted in a large fraction of Tcf1low cells whenFigure 3. Absence of IL12Rb2 or STAT4 from CD8 T Cells Prevents Tcf
(A–H) WT, IL12Rb2/ and STAT4/ P14 chimeric mice were vaccinated with D
(A and E) Tcf1 expression in P14 cells (black open) compared to host CD8 T cells
percentage of Tcf1low P14 cells.
(B and F) IL-2 and IFN-g production by P14 cells following in vitro restimulation wit
(right) in P14 cells.
(C and G) GzmB expression in P14 cells (black open) compared to isotype control
was subtracted.
(D andH) CD127 versus KLRG1 expression among gated P14 cells. The bar graph
MPECs (right).
Bar graphs depict means (±SD, n = 5). Data are representative of at least 2 ind
ANOVA tests (***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant [p > 0.05]). SP14 cells were wild-type, but not when they lacked IL12Rb2 or
STAT4 (Figure 3E). The latter was associated with reduced
effector differentiation (Figures 3F and 3H), in agreement with
Keppler et al. (2009). Again, GzmB expression was not different
(Figure 3G). Thus, Tcf1 downregulation and effector differentia-
tion in response to DC vaccination and bacterial infection de-
pends on IL-12Rb2-STAT4 signaling in CD8 T cells.
IL-12-Mediated Tcf1 Downregulation Depends on Cell
Cycling and Occurs at the Level of Gene Expression
We further addressed the mechanisms of IL-12-mediated Tcf1
downregulation. P14 cells stimulated in vitro using gp33 pep-
tide-pulsed splenocytes maintained high Tcf1 expression
through multiple cell divisions (Figure 4A), in agreement with
Lin et al. (2016). IL-12 induced precipitous Tcf1 downregulation
after 48 hr of activation (Figure 4B). To address whether this
drop in Tcf1 expression required cell division, we blocked cell-
cycle progression after 48 hr of stimulation using aphidicolin.
Cell-cycle blockade prevented Tcf1 downregulation (Figure 4C),
demonstrating that IL-12-induced Tcf1 loss was cell-cycle
dependent.
We next investigated whether IL-12 regulated Tcf1 at the level
of gene expression. The addition of IL-12 during activation of P141 Downregulation during Vaccination and Bacterial Infection
C33 or DC33/CpG (A–D) or infected with L.m.-gp33 (E–H).
(gray open) and Tcf7/ P14 cells (control) (gray fill). The bar graph depicts the
h gp33 peptide. The bar graphs depict the percentage of IL-2+ (left) and IFN-g+
(gray fill). The bar graph depicts theMFI of GzmB staining whereby background
s indicate the percentage of CD127KLRG1+ SLECs (left) andCD127+ KLRG1
ependent experiments. Statistical significance was determined with one-way
ee also Figure S3.
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Figure 5. Tcf7/ CD8 T Cells Undergo Effector Differentiation Even in the Absence of Systemic Inflammation
WT or Tcf7/ P14 chimeric mice were vaccinated with DC33 or DC33/CpG.
(A) Abundance of P14 cells (CD45.2+) in the spleen at day 7 post-vaccination.
(B) IL-2 and IFN-g production by P14 cells following in vitro restimulation with gp33 peptide. The bar graphs show the percentage of P14 cells producing IL-2 (left)
and IFN-g (right).
(C) GzmB expression (black open) compared to isotype control (gray fill). The bar graph shows the MFI of GzmB staining whereby background was subtracted.
(D) CD127 versus KLRG1 expression among gated P14 cells. The bar graphs show the percentage of CD127 KLRG1+ SLECs (left) and CD127+ KLRG1
MPECs (right).
(E) Tcf7lox/lox R26-lox-YFP P14 cells (CD45.2+) were treated with Tat-Cre in vitro, and the frequency of YFP+ P14 cells (Tcf7 deleted) was determined after 48 hr of
culture in vitro (left). Histogram overlay shows Tcf1 expression by flow-sorted YFP+ (gray fill) and YFP P14 cells (black open) (right). Numbers indicate the
percentage of cells in the respective quadrants (left) and the percentage of Tcf1hi cells (right).
(legend continued on next page)
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cells with gp33 peptide-pulsed splenocytes strongly reduced
Tcf7 mRNA levels (Figure 4D), indicating that IL-12 silenced
Tcf7. The magnitude of the transcriptional effect (19.6- and
15.2-fold in two independent experiments) even exceeded the
reduction in Tcf1 protein expression (9.0±1.7-fold, n = 6) (Fig-
ure S3C). A role for IL-12-induced transcriptional silencing was
further addressed using the DNA methyltransferase inhibitor
5-aza-2-deoxycytidine (decitabine). Decitabine addition (at
48 hr post-stimulation) prevented IL-12-mediated Tcf1 suppres-
sion in part (Figure 4E). Reduced Tcf1 suppression in the pres-
ence of decitabine was not due to reduced cell cycling (data
not shown). The data show that IL-12-induced Tcf1 suppression
depended on cell division, was explained by reduced gene
expression, and depended in part on DNA methylation, collec-
tively suggesting a role for epigenetic Tcf7 silencing.
Primed CD8 T Cells Lacking Tcf1 Undergo Default
Effector Differentiation
The observation that inflammation suppressed Tcf1 and pro-
moted effector differentiation raised the question regarding the
causal relationship between these two events. Inflammation-
dependent Tcf1 suppression may be a prerequisite for effector
differentiation. Conversely, inflammation may induce effector
differentiation and that leads to Tcf1 suppression. Finally, inflam-
mation may independently promote effector differentiation and
inhibit Tcf1 expression. If Tcf1 suppressed effector differentia-
tion, Tcf7/ CD8 T cells should differentiate more efficiently
into effector cells than WT cells.
In response to DC33/CpG vaccination, WT and Tcf7/ P14
cells expanded comparably (Figure 5A). However, Tcf7/ P14
cells expressed less IL-2 and more GzmB and differentiated
more efficiently into SLECs than WT P14 cells (Figures 5B–5D).
Interestingly, considerable effector differentiation of Tcf7/
P14 cells was also observed in response to DC33 in the absence
of systemic inflammation (Figures 5B–5D). Thus, lack of Tcf1 re-
sulted in default effector differentiation.
The above experiments were performed with P14 cells from
mice with germline Tcf7 deletion, in which T cell development
is significantly impaired (Ioannidis et al., 2001; Verbeek et al.,
1995). It was thus possible that increased effector differentiation
was somehow the consequence of altered T cell development.
To rule this out, we generated Tcf7lox/lox mice harboring a
Rosa26 lox stop lox EYFP cassette (R26-stop-YFP) and a P14
TCR transgene (schematically shown in Figure S4A). Exposure
of naive P14 Tcf7lox/lox R26-stop-YFP cells to Tat-Cre fusion pro-
tein in vitro resulted in YFP expression in a considerable fraction
of P14 cells. Importantly, the vast majority of the YFP+ cells
lacked Tcf1 protein expression, while most YFP cells were
Tcf1+ (Figure 5E). Thus, YFP induction could be used to track
Tcf7-deleted cells at the single-cell level.(F) Tat-Cre-treated Tcf7lox/lox R26-lox-YFP P14 cells (CD45.2+) were transferred
YFP+ P14 cells (Tcf7 deleted) was determined 7 days later (left). Tcf1 expression
indicate the percentage of cells in the respective quadrants (left) and the percen
(G and H) Gated YFP+ (Tcf7-deleted) and YFP P14 cells (non-deleted) were a
CD127 KLRG1+ SLECs and CD127+ KLRG1 MPECs (H). Bar graphs depict m
Data are representative of at least two independent experiments. Statistical s
*p < 0.05; ns, not significant [p > 0.05]). See also Figure S4.Next, we adoptively transferred Tat-Cre-treated P14 Tcf7lox/lox
R26-stop-YFP cells (CD45.2+) into CD45.1+ recipient mice,
which were then vaccinated with DC33. The fraction of YFP+
P14 cells (Tcf7 deleted) at day 8 corresponded to that of input
(Figures 5E and 5F), indicating comparable expansion of YFP+
(Tcf7 deleted) and YFP cells (nondeleted). We confirmed
that YFP+ cells were mostly Tcf1 and that YFP cells were
predominantly Tcf1+ (Figure 5F). As expected, YFP P14 cells
(nondeleted) were IL-2hi, GzmBlow and predominantly CD127+
KLRG1 MPECs. In contrast, YFP+ P14 cells (Tcf7-deleted)
were IL-2low, GzmBhi and predominantly CD127 KLRG1+
SLECs (Figures 5G and 5H). Thus, default effector differentiation
of T cells lacking Tcf7 was observed when Tcf1 was deleted in
naive CD8 T cells and was thus entirely independent of a devel-
opmental defect. Altogether, these data showed that Tcf1 coun-
teracted effector differentiation and that inflammation-induced
Tcf1 suppression was needed for effector differentiation.
Lack of Tcf1 Prevents Default Central Memory
Formation in Response to Vaccination
Exposure to antigen in the context of DCs but in the absence of
systemic inflammation results in default memory formation
(i.e., accelerates the rate at which CD8 T cells acquire late-mem-
ory characteristics) (Badovinac et al., 2005). As we observed
default effector differentiation of Tcf7/ CD8 T cells during DC
vaccination, we next asked whether this impacted memory for-
mation. WT and Tcf7/ P14 cells were readily detected
>40 days after DC33 vaccination, although Tcf7/ P14 memory
cells were slightly reduced (p = 0.08) (Figure 6A). While CD127+
CD62L effector memory cells were present normally, CD127+
CD62L+ central memory (TCM) cells were severely (>10-fold)
reduced among Tcf7/ as compared to WT P14 cells (Fig-
ure 6B). In agreement with reduced default central memory for-
mation, Tcf7/memory cells produced less IL-2 but expressed
more GzmB (Figures 6C and 6D). Finally, equal numbers of flow-
sortedmemory P14 cells were transferred to naive secondary re-
cipients, which were then challenged with LCMV cl13. While WT
P14 memory cells expanded efficiently, the recall expansion of
Tcf7/ P14 memory cells was greatly reduced (Figure 6E). Cor-
responding results were obtained when P14 chimeric mice
had been vaccinated with DC33/CpG (Figures S4B–S4F). We
conclude that the formation of default central memory in
response to vaccination depends on Tcf1 and that deficient cen-
tral memory differentiation in the absence of Tcf1 is associated
with default effector differentiation during the primary response.
Tcf1 Suppresses IL12Rb2 and Transcription Factors
Promoting Effector Differentiation
While naive T cells express low levels of IL-12R, both IL-12R
chains are upregulated following T cell activation (Trinchieri,into CD45.1+ mice, which were then vaccinated with DC33. The frequency of
by flow sorted YFP+ (gray fill) and YFP P14 cells (black open) (right). Numbers
tage of Tcf1hi cells (right).
nalyzed for the percentage of cells producing IL-2 (G) and the percentage of
eans (±SD, n = 5).
ignificance was determined with unpaired t tests (***p < 0.001; **p < 0.01;
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Figure 6. Tcf1 Is Essential for Default Central Memory Formation in
Response to DC33 Vaccination
WT or Tcf7/ P14 chimeric mice were vaccinated with DC33.
(A) Abundance of P14 cells in the spleen 40 days post-vaccination.
(B) CD127 versus CD62L expression among gated P14 cells. The bar graphs
show the percentage of CD127+ CD62L+ (central memory phenotype) cells.
(C) IL-2 and IFN-g production by P14 cell following in vitro restimulation. The
bar graphs depict the percentage of IL-2+ (left) and IFN-g+ (right) P14 cells.
(D) GzmB expression in P14 cells (black open) compared to isotype control
(gray fill). Numbers indicate the MFI of staining, and the bar graph depicts the
MFI of GzmB staining whereby background was subtracted.
(E) WT and Tcf7/ P14 memory cells (CD45.2+) were flow sorted, and equal
numbers (104 cells) were transferred into secondary recipients (CD45.1+),
which were infected with LCMV cl13. The abundance of P14 cells was
determined 8 days later. The bar graph shows fold expansion of P14 cells
compared to input, assuming 10% take of input cells.
Bar graphs depict means (±SD, n = 3–5). Data are representative of two in-
dependent experiments. Statistical significancewas determined with unpaired
t tests (***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant [p > 0.05]). See also
Figure S4.2003). This improves IL-12 responsiveness, enhances STAT4
activation and further increases the expression of the STAT4
target IL-12Rb2, thus generating an IL-12-dependent feedback
loop (Becskei and Grusby, 2007), which promotes effector
differentiation. Here, we find that IL-12Rb2-STAT4 signaling sup-
pressed Tcf1 and that Tcf1 expression counteracted effector dif-
ferentiation. To do the latter efficiently, we hypothesized that2114 Cell Reports 22, 2107–2117, February 20, 2018Tcf1 negatively regulated IL12Rb2. Indeed, following DC33
vaccination, IL12Rb2was significantly overexpressed in Tcf7/
as compared to WT MPECs (Figure 7A). IL12Rb2 expression in
Tcf7/MPECswas as high as inWT SLECs. Inspection of avail-
able chromatin immunoprecipitation sequencing (ChIP-seq)
data (Xing et al., 2016) revealed that Tcf1 is associated with
the IL12Rb2 locus in CD8+ thymocytes (Figure S5A). Thus,
Tcf1 expression limited effector differentiation at least in part
by counteracting IL12Rb2 upregulation and consequently by
reducing IL-12 responsiveness.
To further address the basis for default effector and deficient
central memory differentiation, we investigated the expression
of key transcription factors involved in effector and memory dif-
ferentiation. Among transcription factors involved in memory dif-
ferentiation, Tcf7/ and WT MPECs expressed comparable
levels of Bcl6, while Eomes was increased in Tcf7/ MPECs
(Figure 7B). These expression patterns did not explain deficient
memory formation in the absence of Tcf1. On the other hand,
compared to WT, Tcf7/ MPECs overexpressed several tran-
scription factors mediating effector differentiation (i.e., Prdm1,
Tbx21, Id2, and Zeb2). Except for Zeb2, Tcf7/ MPECs ex-
pressed these transcription factors at equal or even higher levels
as compared toWTSLECs (Figure 7C). Tcf1 was associated with
the Prdm1, Tbx21, and Id2 loci, but not the Zeb2 locus, in CD8+
thymocytes (Figure S5B), indicating both direct and indirect reg-
ulatory mechanisms. Thus, upregulation of IL12Rb2 and several
transcription factors promoting effector differentiation in MPECs
can account for the default effector differentiation of primed CD8
T cells lacking Tcf1.
DISCUSSION
Unlike other transcription factors required for memory formation,
Tcf1 is expressed at high levels in naive CD8 T cells and is down-
regulated inmost CD8 T cells during the primary response to viral
or bacterial infection (Boudousquie´ et al., 2014; Jeannet et al.,
2010; Lin et al., 2016; Zhou et al., 2010), which correlates with
effector differentiation. The signals mediating Tcf1 downregula-
tion in vivo and the hierarchical relationship between Tcf1 down-
regulation and effector differentiation have not been elucidated.
Here, we show that IL-12-mediated systemic inflammatory
signals induce Tcf1 downregulation in primed CD8 T cells.
Importantly, CD8 T cells lacking Tcf1 efficiently differentiated
into effector cells even in the absence of systemic inflammation,
indicating that Tcf1 expression counteracted effector differenti-
ation. Thus, IL-12-induced Tcf1 downregulation in wild-type
CD8 T cells facilitated effector differentiation. Tcf1 is also down-
regulated during certain viral infections (Boudousquie´ et al.,
2014; Jeannet et al., 2010; Tiemessen et al., 2014; Wu et al.,
2016; Zhou et al., 2010), which are rich in type I IFN rather than
IL-12. We did obtain evidence that also IFN-b had the capacity
to downregulate Tcf1 in vitro. However, the effect of type I IFN
was surprisingly weak, indicating that additional factors,
perhaps induced by type I IFN, are involved in Tcf1 downregula-
tion during certain viral infections.
Downstream of IL-12R, we find that STAT4 plays an essential
role for Tcf1 suppression. While STATs were originally identified
as transcriptional activators, there is growing evidence that they
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Figure 7. Memory Precursor Cells Lacking
Tcf1 Overexpress IL12Rb2 and Transcription
Factors Promoting Effector Differentiation
(A–C) WT or Tcf7/ P14 chimeric mice were
vaccinatedwith DC33. 7 days later, P14MPECs and
SLECs, as well as naive P14 cells, were flow sorted
and analyzed for the expression of IL12Rb2/ (A),
Bcl6 and Eomes (B), and Prdm1 (Blimp1), Tbx21
(T-bet), Id2, and Zeb2 (C). Gene expression is
shown relative to HPRT. Bar graphs depict means
(±SD) from quadruplicate determinations. Data are
from a single experiment. Equivalent results were
obtained using DC33/CpG vaccination. Statistical
significance was determined with unpaired t tests
(***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant
[p > 0.05]). See also Figure S5.also mediate transcriptional repression (Wei et al., 2010).
Consistent with these latter findings, we show that IL-12 reduced
Tcf7 transcription and that the DNA methyltransferase inhibitor
decitabine partially rescued Tcf1 from IL-12-mediated silencing.
These data are in agreement with an increase of repressive his-
tonemarks (Crompton et al., 2016) and of DNAmethylation at the
Tcf7 locus in effector CD8 T cells (Scharer et al., 2013). A relative
absence of methylated CpG at the Tcf7 locus may explain why
Tcf1 remains highly expressed during the first 2–3 cell divisions,
an observation similarly reported by (Lin et al., 2016). The even-
tual drop in Tcf1 expression may be due to cell cycle and IL-12-
dependent accumulation of CpG methylation at the Tcf7 locus.
During an immune response in vivo, both Tcf1+ and Tcf1 CD8
T cells are present. Maintenance versus downregulation of
Tcf1 may be determined by unequal responsiveness of CD8
T cells to inflammatory signals. This could be based on differen-
tial expression of IL-12R, or components of the respective
signaling pathway, by responding T cells. Indeed, IL12Rb2 is un-
equally expressed in CD8 T cells that have undergone a single di-
vision (Kakaradov et al., 2017). Together with the data shown
herein, it is tempting to speculate that the pool of responding
CD8 T cells diversifies during initial cell divisions and that inflam-
matory signals promote stable effector cell differentiation in part
by silencing Tcf1.
The significance of Tcf1 downregulation emerged from our
finding that CD8 T cells that lacked Tcf1 underwent effector differ-
entiation even in the absence of systemic inflammation. This
‘‘default’’ effector differentiation was associated with impaired
centralmemory formation. The latterwas independent of changes
in the expression of memory promoting transcription factors such
asEomes orBcl6. However,wenotedan inability of DC33-primed
Tcf7/ CD8 T cells to produce IL-2, which is needed for the sec-
ondary expansion of memory CD8 T cells (Feau et al., 2011; Wil-
liams et al., 2006). Naive Tcf7/ CD8 T cells stimulated in vitro
readily produced IL-2 (data not shown), indicating that IL-2 pro-Cell Repoduction was not directly dependent on
Tcf1butwas lostduringpriming.Consistent
with aberrant differentiation, Tcf7/ mem-
ory precursor cells overexpress factors
associated with effector differentiation
such as IL-12Rb2, Prdm1 (Blimp-1), Tbx21(T-bet), Id2, and Zeb2, which likely explains ‘‘default’’ effector dif-
ferentiation and impaired central memory formation
The data included in this paper identify a key role of the IL-12-
STAT4 axis to suppress Tcf1 and consequently to modify mem-
ory versus effector differentiation of CD8 T cells. Interventions
that prevent Tcf1 downregulation may thus be useful to dampen
effector differentiation and reduce autoimmune or allograft re-
sponses. Conversely, approaches to maintain Tcf1 expression
may improve memory formation during vaccination.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (B6) (CD45.2+) mice were purchased from Charles River, and
B6.Cd45.1 (CD45.1+), B6.IL12Rb2/, B6.ROSA26Sortm1(EYFP) (B6.R26-stop-
YFP) mice were obtained from The Jackson Laboratory. B6 P14 TCR Tg
(line 237) (Pircher et al., 1989) mice were provided by H.P. Pircher (Freiburg),
Tcf7/ mice (Verbeek et al., 1995) were provided by H. Clevers (Utrecht)
and backcrossed >12 times to B6, and B6.STAT4/ mice (Kaplan et al.,
1996) were provided by M. Lo¨hning (Berlin). Tcf7-GFP mice have been
described previously (Utzschneider et al., 2016). B6.Tcf7tm1aWtsi/+ mice were
obtained from the International Knockout Mouse Consortium. Founder mice
were crossed to B6 ROSA26:FLPe mice (Jackson Laboratory) to delete the
frt-flanked LacZ-neo cassette and to generate B6.Tcf7tm1c mice, in
which exon 4 of Tcf7 is flanked with loxP sites (B6.Tcf7lox). P14 Tcf7/, P14
Axin2LacZ/+, OT1 Axin2LacZ/+, P14 Tcf7/, P14 Tcf7-GFP, P14 IL-12Rb2/,
P14 STAT4/, and P14 Tcf7lox/lox R26-stop-YFP strains were generated by
breeding. As controls for Tcf7/ mice, we used wild-type (WT) Tcf7+/+ litter-
mate or B6 mice. Mice were bred and maintained in a specific-pathogen-
free (SPF) environment, vaccinated in a conventional environment, and
infected in the P2 animal facility of the University of Lausanne. Experiments
were performed in 6- to 12-week-old male and female mice in compliance
with the University of Lausanne Institutional regulations and were approved
by the veterinarian authorities of the Canton de Vaud.
DC Vaccination and L. monocytogenes Infection
Bone marrow cells derived from B6 (CD45.2+) mice were cultured for 6 days in
granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng/mL) andrts 22, 2107–2117, February 20, 2018 2115
IL-4 (20 ng/mL) (Peprotech). Lipopolysaccharide (100 ng/mL; Sigma) was
added overnight and gp33–41 (gp33) peptide (KAVYNFATM) (10 mg/mL) for
the last 2 hr. The resulting cells (termed DC33) consisted of 50%–80%
CD11c+ cells. One million CD11c+ cells were injected intravenously (i.v.) into
CD45.1+ or CD45.1+2+ recipients with or without 50 mg CpG-B 1826 oligo-
deoxynucleotides (ODNs) administered intraperitoneally (i.p.) (TriLink Biotech-
nologies). 1–2 3 104 purified TCR Tg CD8 T cells (CD45.2+) were adoptively
transferred one day prior to DC injection. Mice were analyzed on day 7 or
day 50 post-vaccination.
L. monocytogenes expressing LCMV gp33-41 (KAVYNFATC) together with
the ovalbumin (OVA257–264)-derived epitope SIINFEKL (N4) or the altered pep-
tide-ligand SIITFEKL (T4) (Oberle et al., 2016) were kindly provided by D. Zehn
(Munich). 2 3 103 colony-forming units (CFUs) were injected i.v. into naive
CD45.1+ mice one day after the adoptive transfer of P14 or OT1 cells. Mice
were analyzed on day 7 post-infection.
Antibody Treatment
Mice were injected i.p. with 500 mg rat anti-mouse IL-12 p40 (C17.8) or with rat
immunoglobulin G2a (IgG2a) isotype control antibody (2A3) (BioXCell) once at
the time of DC vaccination and a second time 5–6 hr later. Mice were analyzed
on day 7 post-vaccination.
Flow Cytometry
Splenocyte suspensions were incubated with anti-CD16/32 (2.4G2) hybrid-
oma supernatant before staining for 15 min at 4C with fluorescent mAbs
(Table S1). Zombie Aqua Fixable Viability Kit (BioLegend) was used to exclude
dead cells.
For intracellular cytokine staining, splenocytes were restimulated in vitro
with gp33-41 peptide (KAVYNFATM) (1 mM) for 5 hr in the presence of brefeldin
A (7 mg/mL) for the last 4.5 hr. Cells were then fixed and permeabilized using
the intracellular fixation and permeabilization buffer kit (eBioscience) and
stained with mAbs against IFN-g, tumor necrosis factor a (TNF-a), and IL-2
(Table S1). The FoxP3 transcription factor staining kit (eBioscience) was
used to detect granzyme B and Tcf1 using specific mAbs (Table S1) followed
by anti-rabbit IgG PE (eBioscience). Flow cytometry analysis was performed
on an LSR-II or LSRFortessa II flow cytometer (BD).
Data Analyses and Statistics
Flow cytometry data were analyzed using FlowJo (TreeStar). Graphics were
prepared with GraphPad Prism. Bar graphs depict the mean ± SEM or SD
as indicated. Statistical analyses were performed using Prism 6.0 (GraphPad
Software) using unpaired t tests (two tailed) or one-way ANOVA as indicated.
p values < 0.05 were considered significant (*p < 0.05; **p < 0.01; ***p < 0.001;
ns, nonsignificant [i.e., p values > 0.05]).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.01.072.
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